Three new Directors appointed, page-10

Just to give a sense of timeframes with respect to Lankau’s time at Endo…

Lankau commenced as Senior VP at Endo in the US shortly after Endo launched the Lidoderm (lidocaine) patch into the US (launched late 1999). The Lidoderm patch was the first FDA approved product for the pain of PHN. By the time Lankau resigned as CEO of Endo in 2008, sales had grown to $700m+ pa.

In 2006, when Lankau was CEO, Endo received FDA approval for and launched Opana (extended- release oxymorphone). In the same year Endo also licensed and launched Synera, a lidocaine/tetracaine patch for needle-stick pain.

Lankau would have also been instrumental in the negotiation of Endo’s licensing deal with Novartis to sell Voltaren (diclofenac gel) in the US. The Voltaren deal announcement came just three days after Lankau’s departure from Endo in March, 2008.

Included in Phosphagenics current pipeline are the following TPM products

• diclofenac gel
• diclofenac patch
• lidocaine gel
• lidocaine patch
• oxymorphone transdermal patch
• oxycodone topical patch(currently in clinical trials for PHN)

I think it would be fair to say that there would be few people in the world better qualified than Lankau to assess the efficacy and commercial potential of POH’s suite of TPM pain products. Clearly he saw something that he liked!